论文部分内容阅读
目的通过乳腺癌血清蛋白质芯片检测来分析乳腺癌的预后差异,寻找新的判断预后的指标,以期为临床治疗方案的选择提供有价值的依据。方法采用美国Ciphergen公司生产的蛋白质芯片阅读机,选择IMAC-3和WCX-2两种芯片,对64例乳腺癌患者血清进行研究。64例乳腺癌患者全部随访5年,死亡13例。采用Ciphergen proteinchip3.0软件分析乳腺癌患者血清的蛋白质谱。将13例死亡患者的蛋白质图谱与其余患者的进行比对,差异比较采用t检验,P<0.05为有统计学意义。结果在WCX-2蛋白芯片,有2个位点,相对分子质量(Mr)分别为9405和6424的位置,死亡与生存乳腺癌患者的血清蛋白峰表达有差异,在Mr9405的位置,生存乳腺癌患者低表达;在Mr6424的位置,生存乳腺癌患者高表达,敏感性为76.9%～84.6%,特异性为76.4%～80.3%。在IMAC-3蛋白芯片,发现有2个位点,Mr分别为4643和5910的位置,死亡与生存的乳腺癌患者血清蛋白峰表达有差异,生存乳腺癌患者高表达,敏感性为61.5%～76.9%,特异性为68.6%～74.5%。结论死亡与生存乳腺癌患者血清蛋白峰表达存在差异,有可能成为新的判断乳腺癌预后的指标。
OBJECTIVE: To analyze the prognostic difference of breast cancer by detecting serum protein chip of breast cancer and to find new indexes to judge the prognosis, in order to provide valuable evidences for clinical treatment options. Methods Using the protein chip reader manufactured by Ciphergen Company in the United States, two kinds of chips, IMAC-3 and WCX-2, were selected to study the serum of 64 breast cancer patients. Sixty-four breast cancer patients were followed up for 5 years and 13 died. Serum protein profiles of breast cancer patients were analyzed using Ciphergen proteinchip 3.0 software. The protein profiles of 13 death patients were compared with those of the remaining patients, and the differences were compared using t test, P <0.05 was considered statistically significant. Results There were 2 sites in the WCX-2 protein chip with relative molecular mass (Mr) of 9405 and 6424, respectively. There was a difference in serum protein peak between death and survival breast cancer patients. At the site of Mr9405, the survival of breast cancer The expression of Mr6424 was high in patients with breast cancer, the sensitivity was 76.9% -84.6%, and the specificity was 76.4% -80.3%. In the IMAC-3 protein chip, we found two sites, Mr 4643 and 5910, respectively. There was a difference in the serum protein peak between death and survival in breast cancer patients. The expression of IMT protein in breast cancer patients with high expression was 61.5% 76.9%, the specificity is 68.6% ~ 74.5%. Conclusion There are differences in serum protein peak expression between death and survival breast cancer patients, which may become a new index to judge the prognosis of breast cancer.